Could Gelteq’s (GELS) Gel Improve Oral Drug Delivery?

When we think about pharmaceutical innovation, we tend to think about the drug itself. A new molecule, a new treatment, a new way to target a disease.

But there is another part of the equation that can matter just as much: how the medicine gets into the body.

A drug can be effective and still create problems for the person taking it. It may be difficult to swallow, unpleasant to take, poorly absorbed or require an injection when an oral formulation would be more convenient. Solving those problems doesn't necessarily require discovering another drug. Sometimes, it requires finding a better way to deliver the one that already exists.

That's the opportunity Gelteq (GELS) is pursuing.

How Gelteq’s gel approaches oral drug delivery

The Australian biotechnology company has developed a proprietary gel-based delivery platform designed to formulate active ingredients into an ingestible gel. Gelteq claims its technology can be adapted for different ingredients and applications, with a focus on issues including formulation, absorption, dosing and patient experience.

That distinction matters. The delivery system isn't necessarily the medicine. It can be the solution to a problem surrounding the medicine.

What the early results show

Gelteq has reported encouraging results from preclinical testing. Its technology page cites more than 40% higher bioavailability for water-soluble compounds and 300% faster absorption during the first hour for an oil-soluble compound. The company has also reported bioequivalence for a BCS Class III compound. These remain company-reported results, rather than evidence of proven clinical benefit, but they show the kinds of formulation challenges Gelteq is trying to address.

And the company isn't limiting that effort to one product.

Gelteq's pharmaceutical pipeline includes human clinical development, a diabetes preclinical program and work on incorporating peptides and peptide-based therapeutics into oral formulations. That last area is particularly interesting because some peptide therapies have traditionally relied on injections, making delivery itself part of the challenge. Gelteq is also developing formulations for animal health, where it has completed canine palatability trials and begun a clinical trial for an antiparasitic candidate.

That breadth gives the platform a different kind of potential. If the same underlying delivery technology can solve different formulation problems across human pharmaceuticals, veterinary medicine and consumer health, Gelteq doesn't necessarily need to win one enormous market. It needs to demonstrate that its technology can solve specific problems well enough that customers want to use it again.

Proving it commercially

The company is now trying to prove that proposition commercially.

Gelteq has manufactured a commercial product for an East Asian customer and established a Center of Excellence in Guangdong Province, China, to expand product development and testing capabilities. It also secured up to $3.5 million in strategic debt financing in May to support commercialization and clinical programs.

That puts Gelteq at an interesting point in its development. The technology has to move from promising formulation work to clinical evidence, regulatory progress, customer adoption and repeat commercial orders.

For investors, that's what makes the journey worth watching.

What's next for Gelteq?

The near-term milestones are relatively straightforward: clinical programs, regulatory progress, new commercial products and customer relationships. The longer-term question is bigger. Can a delivery solution that addresses one set of pharmaceutical problems become a repeatable platform across many different products and markets?

If it can, the value may not come from replacing every pill with a gel.

It could come from removing a layer of friction that patients, drug developers and healthcare companies have simply had to work around.

And sometimes, that's where a niche becomes much more interesting than it first appears.

Clinical programs, regulatory progress, and new customer orders are all still ahead. Track Gelteq’s milestones on a free Watchlist as they land.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Simply Wall St analyst Chrissy Paradis and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.